@FierceMedDev: St. Jude faces escalation of shareholder lawsuits over Durata leads. Article | Follow @FierceMedDev
@MarkHFierce: Nanostim says it successfully implanted leadless cardiac pacers into 11 patients in the Czech Republic. Major progress. News | Follow @MarkHFierce
@DamianFierce: Critical Diagnostics has inked distribution deals for its heart test with Quest ($DGX) and LabCorp ($LH). More | Follow @DamianFierce
> Medical device startup EndoStim raised more than $8 million of a total $12 million fundraising round. Story
> Chembio Diagnostics won FDA approval for its new HIV oral fluid or blood sample diagnostic test, and investors drove the stock up to a new high for the year. Item
> Expect more congressional scrutiny and FDA recalls in 2013, a new report concludes. Item
> The device tax isn't the only reason that 2013 will be a struggle for medical device companies. Story
> In vitro diagnostics company Venaxis has appointed a Beckman Coulter executive to its board of directors. Item
> Halma, a maker of various health technologies in the U.K., is snatching up ophthalmic surgical products company MicroSurgical Technology for at least $57 million. Story
Biotech News
@FierceBiotech: Add a drop of blood, and this tiny Dx device tests 50 things at once. Story | Follow @FierceBiotech
@JohnCFierce: Halozyme gets $8M upfront and a bunch of potential biobucks in drug delivery collab with Pfizer. Release | Follow @JohnCFierce
@RyanMFierce: Halozyme rebounds with $8M Pfizer biologics pact. More | Follow @RyanMFierce
> Transcept caps a tough year with PhII drug failure. Article
> Merck's big PhIII failure on cholesterol drug spurs an EMA review. Report
> Raptor gets $50M loan to back launch of rare disease drug. News
> Karolinska Development inks a $33M deal on a batch of its projects. Story
Pharma News
@FiercePharma: Smaller players looking for expansion deals, too. News | Follow @FiercePharma
> Sanofi animal health deal puts it in India. More
> India vaccine makers see China undercutting them. Story
> EMA having second thoughts about Merck's Tredaptive. Item